Olgu Sunumu
BibTex RIS Kaynak Göster

Osteosarcoma of rib treated with regorafenib: a case report

Yıl 2021, Cilt: 3 Sayı: Supplement 1, 62 - 64, 07.03.2021
https://doi.org/10.46310/tjim.875951

Öz

Osteosarcoma is a common primary malignant bone tumor in young adults presenting with back and chest pain complaints. Here, we presented a rare case of osteosarcoma.

Destekleyen Kurum

Bursa Uludag University Faculty of Medicine

Teşekkür

We thank our patient for allowing her data to be used in this scientific study

Kaynakça

  • Mirabello L, Troisi R J, Savage S A. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009 Apr 1;115(7):1531-43. doi: 10.1002/cncr.24121.
  • Davis L E, Bolejack V, Ryan C W, Ganjoo K N, Loggers E T, Chawla S, Agulnik M, Livingston M B, Reed D, Keedy V, Rushing D, Okuno S, Reinke D K, Riedel R F, Attia S, Mascarenhas L, Maki R G. Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma. J Clin Oncol . 2019 Jun 1;37(16):1424-1431. doi: 10.1200/JCO.18.02374.
  • Duffaud F, Mir O, Boudou-Rouquette P, Piperno-Neumann S, Penel N, Bompas E, Delcambre C, Kalbacher E, Italiano A, Collard O, Chevreau C, Saada E, Isambert N, Delaye J, Schiffler C, Bouvier C, Vidal V, Chabaud S, Blay JY, French Sarcoma Group. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 2019 Jan;20(1):120-133. doi: 10.1016/S1470-2045(18)30742-3.
Yıl 2021, Cilt: 3 Sayı: Supplement 1, 62 - 64, 07.03.2021
https://doi.org/10.46310/tjim.875951

Öz

Kaynakça

  • Mirabello L, Troisi R J, Savage S A. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009 Apr 1;115(7):1531-43. doi: 10.1002/cncr.24121.
  • Davis L E, Bolejack V, Ryan C W, Ganjoo K N, Loggers E T, Chawla S, Agulnik M, Livingston M B, Reed D, Keedy V, Rushing D, Okuno S, Reinke D K, Riedel R F, Attia S, Mascarenhas L, Maki R G. Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma. J Clin Oncol . 2019 Jun 1;37(16):1424-1431. doi: 10.1200/JCO.18.02374.
  • Duffaud F, Mir O, Boudou-Rouquette P, Piperno-Neumann S, Penel N, Bompas E, Delcambre C, Kalbacher E, Italiano A, Collard O, Chevreau C, Saada E, Isambert N, Delaye J, Schiffler C, Bouvier C, Vidal V, Chabaud S, Blay JY, French Sarcoma Group. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 2019 Jan;20(1):120-133. doi: 10.1016/S1470-2045(18)30742-3.
Toplam 3 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular İç Hastalıkları
Bölüm Case Reports
Yazarlar

Orkun Sakar 0000-0002-1624-4339

Cemre Uçaryılmaz 0000-0002-5758-1120

Ahmet Bilgehan Şahin 0000-0002-7846-0870

Türkkan Evrensel 0000-0002-9732-5340

Cengiz Gebitekin 0000-0001-8718-9499

Yayımlanma Tarihi 7 Mart 2021
Gönderilme Tarihi 7 Şubat 2021
Kabul Tarihi 6 Mart 2021
Yayımlandığı Sayı Yıl 2021 Cilt: 3 Sayı: Supplement 1

Kaynak Göster

EndNote Sakar O, Uçaryılmaz C, Şahin AB, Evrensel T, Gebitekin C (01 Mart 2021) Osteosarcoma of rib treated with regorafenib: a case report. Turkish Journal of Internal Medicine 3 Supplement 1 62–64.

e-ISSN: 2687-4245 

Turkish Journal of Internal Medicine, hosted by Turkish JournalPark ACADEMIC, is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

by-nc-nd.png
2024 -TJIM.org